Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250 Compliance
LaFleur Minerals Engages Leading Executive Search Firm to Recruit Senior Mining Executive as Company Advances Toward Gold Production
SAGA Metals Closes on Title Transfer Agreement to Expand Wolverine Heavy Rare Earth Element Project in Labrador-Grab Sample Assays Included up to 21.6% TREO
